O-P04 Sonodynamic Therapy Complements PD-L1 Immune Checkpoint Inhibition in a Murine Model of Pancreatic Cancer

Medicine and Dentistry

• Back 9%
• Bilateral Cancer 9%
• Cancer Model 9%
• Cancer Therapy 9%
• CD8 Antigen 18%
• Cell Death 9%
• Chemotherapy 9%
• Cytotoxicity 9%
• Diseases 9%
• Flow Cytometry 9%
• Immune Checkpoint Inhibitor 63%
• Immunoglobulin 9%
• Immunotherapy 9%
• Monoclonal Antibody 9%
• Neoplasm 90%
• Oncology 9%
• Pancreas Cancer 100%
• Programmed Death-Ligand 1 100%
• Reactive Oxygen Species 9%
• Receptor 9%
• Sensitization 9%
• Sonodynamic Therapy 100%
• Tumor Model 18%
• Tumor Progression 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Bilateral Cancer 9%
• Cancer Model 9%
• CD8 Antigen 18%
• Chemotherapy 9%
• Cytotoxicity 9%
• Diseases 9%
• Flow Cytometry 9%
• Immune Checkpoint Inhibitor 63%
• Immunoglobulin 9%
• Immunotherapy 9%
• Malignant Neoplasm 9%
• Monoclonal Antibody 9%
• Neoplasm 100%
• Pancreas Cancer 100%
• Reactive Oxygen Metabolite 9%
• Receptor 9%
• Tumor Growth 9%
• Tumor Model 18%

Immunology and Microbiology

• Adaptive Immune System 18%
• Back 9%
• C57BL Mouse 9%
• CD4 18%
• CD8 18%
• Cell Death 9%
• Cytotoxicity 9%
• Growth Regulation 9%
• Immunotherapy 9%
• Intravenous Immunoglobulin 9%
• Microbubble 18%
• Monoclonal Antibody 9%
• Programmed Death-Ligand 1 100%
• Sensitization 9%
• T Cell 18%
• Tumor Immunity 9%
• Tumor Volume 9%